UPDATE 2-Merck pushes deeper into targeted cancer therapy with $2.7 bln ArQule deal

Merck & Co Inc said on Monday it would buy ArQule Inc for $2.7 billion, as it looks to tap into the drug developer's experimental blood cancer therapy that targets genetic mutations.